Skip to main content

Advertisement

Table 7 The impact of clinicopathologic parameters on prognosis by univariate analysis

From: Metabolic phenotypes in primary unknown metastatic carcinoma

Clinicopathologic parameters No. of patients (n = 59*) (%) Overall survival
No. of cases Patient death Median survival (95% CI) (months) P -value
Age     0.326
 <50 20 5 96 (70–123)  
 ≥50 39 13 43 (30–56)  
Sex     0.539
 Male 35 10 88 (65–110)  
 Female 24 8 74 (44–103)  
Histologic subtype     0.002
 AD 21 11 23 (10–36)  
 PD 13 1 34 (28–40)  
 SQ 17 5 49 (33–65)  
 UD 8 1 115 (86–145)  
Clinical subtype     <0.001
 Nodal type 25 3 107 (88–126)  
 Single organ type 10 1 119 (95–143)  
 Intermediate type 10 4 21 (9–32)  
 Carcinomatosis type 14 10 6 (3–10)  
Organs involved     0.701
 Lymph node 38 12 77 (55–99)  
 Bone 6 2 40 (18–62)  
 Brain 7 1 31 (23–39)  
 Other 8 3 83 (40–126)  
Postoperative treatment     0.638
 None 7 1 107 (75–139)  
 Chemotherapy 20 7 77 (45–108)  
 Radiation therapy 15 4 52 (36–68)  
 Chemo-radiation therapy 17 6 25 (18–33)  
  1. PD: poorly differentiated carcinoma, AD: adenocarcinoma, SQ: squamous cell carcinoma, UD: undifferentiated carcinoma.
  2. *Out of 77 patients, clinical follow-up data were available in 59 patients.
  3. Bold represents p<0.05.